Cancer Advisor

Exciting results for a new first line option in PD-L1+ mTNBC (pretreated metastatic TNBC). Background: Although PD-1/PD-L1* inhibitors plus chemo have expanded treatment options for previously untreated PD-L1–positive advanced TNBC, there still remains a critical unmet need to improve outcomes. SG previously demonstrated significant clinical benefit in pretreated metastatic TNBC (mTNBC). We report results from the ASCENT-04/KEYNOTE-D19 study   in patients with previously untreated, PD-L1–positive (CPS ≥ 10; 22C3 assay) locally advanced unresectable or mTNBC. Note: PD-L1 stands for programmed death ligand 1. It's a protein found on some normal cells and can be expressed on cancer cells. It acts as a brake on the immune system, preventing T cells from attacking other cells, including cancer cells. When PD-L1 binds to another protein called PD-1, it inhibits T cell activity. ( National Cancer Institute ) Methods: Patients were randomized 1:1 to SG (10 mg/kg IV, day 1 & 8) + pembro...

Many of us have been personally affected by cancer — including me. I’m an oncologist, and my own family history is one of the reasons I decided to specialize in caring for people with cancer and in conducting cancer research. My mom has lung cancer, and several relatives from both my mom and my dad’s side were also diagnosed with cancers. It’s no wonder I worry about cancer affecting me one day. Credit: Cancer Care (2nd Edition) About 1 in 5 people around the world will  develop cancer  throughout the course of their lives. In 2021, almost 1.8 million  new cancer cases  were reported in the United States, according to the Centers for Disease Control and Prevention. The following year, about 600,000 people died of cancer in the country. But there are steps you can take to reduce your risk. About 40 percent of new cancer diagnoses in U.S. adults age 30 and older are considered preventable, according to a  study  from the American Cancer Society. Here are 11...

Repurposed non-cancer drugs have emerged as a powerful strategy to overcome chemo-resistance in cancer therapy by targeting multiple mechanisms that cancer cells use to evade standard chemotherapy. This approach offers faster, cost-effective alternatives to developing new drugs and leverages existing safety and pharmacokinetic knowledge. How Repurposed Drugs Reverse Chemoresistance Multi-targeting cancer hallmarks and signaling pathways:  Many repurposed drugs act on key cancer hallmarks such as sustaining proliferative signaling, evading growth suppressors, resisting cell death, and activating invasion/metastasis. They modulate pathways involved in drug resistance, including PI3K-AKT, WNT, NOTCH, and TGF-β, thereby restoring sensitivity to chemotherapy 3 . Modulating tumor microenvironment (TME):  Repurposed drugs can alter the TME to reduce protective niches for cancer cells, enhance immune responses, and disrupt stromal support that contributes to drug resistance 3 2 . Tar...